HOOKIPA PharmaHOOK 50 PB Ratio is 0.49 as of Jun. 30, 2026, which is 47% below its 10-year median of 0.92. GuruFocus rates HOOK with a GF Score™ of 50/100 and a GF Value™ of $2.78 (Possible Value Trap). The stock has 7 warning signs investors should review. Among 1,229 Biotechnology companies, HOOKIPA Pharma ranks better than 95.04% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-06-30), HOOKIPA Pharma's share price is $1.15. HOOKIPA Pharma's Book Value per Share for the quarter that ended in Jun. 2025 was $2.35. Hence, HOOKIPA Pharma's PB Ratio of today is 0.49.
Warning Sign:
HOOKIPA Pharma Inc stock PB Ratio (=0.49) is close to 1-year high of 0.52.
The historical rank and industry rank for HOOKIPA Pharma's PB Ratio or its related term are showing as below:
HOOK'
s PB Ratio Range Over the Past 10 Years
Min: 0.27 Med: 0.92 Max: 8.05
Current: 0.49
During the past 8 years, HOOKIPA Pharma's highest PB Ratio was 8.05. The lowest was 0.27. And the median was 0.92.
HOOK's PB Ratio is ranked better than 95.04% of 1229
companies
in the Biotechnology industry
Industry Median: 2.86
vs HOOK: 0.49
During the past 12 months, HOOKIPA Pharma's average Book Value Per Share Growth Rate was -67.10% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -32.30% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -27.50% per year.
During the past 8 years, the highest 3-Year average Book Value Per Share Growth Rate of HOOKIPA Pharma was -11.90% per year. The lowest was -32.60% per year. And the median was -32.30% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
HOOKIPA Pharma PB Ratio Related Terms
HOOKIPA Pharma PB Ratio Historical Data
* Premium members only.
The historical data trend for HOOKIPA Pharma's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, HOOKIPA Pharma's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
HOOKIPA Pharma PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, HOOKIPA Pharma's PB Ratio distribution charts can be found below:
* The bar in red indicates where HOOKIPA Pharma's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
HOOKIPA Pharma's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
HOOKIPA Pharma (HOOK) has a PB Ratio of 0.49 as of Jun. 30, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on HOOKIPA Pharma and its competitors. This is 47% below median its historical median of 0.92. Over the past decade, HOOKIPA Pharma's PB Ratio has ranged from 0.27 to 8.05. According to the industry distribution chart, HOOKIPA Pharma ranks #61 out of 1229 companies in the Biotechnology industry, placing it in the top 5%.
Is HOOKIPA Pharma's PB Ratio too high?
HOOKIPA Pharma's current PB Ratio of 0.49 is 47% below median its 10-year median of 0.92. Over the past 10 years, this metric has ranged from a low of 0.27 to a high of 8.05. The Biotechnology industry median PB Ratio is 2.86. HOOKIPA Pharma's value of 0.49 is 82.9% below this industry median. Based on the distribution chart, HOOKIPA Pharma ranks #61 out of 1229 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, HOOKIPA Pharma has a GF Score™ of 50/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does HOOKIPA Pharma's PB Ratio compare to COCP and LNAI?
According to the Biotechnology industry distribution chart, HOOKIPA Pharma ranks #61 out of 1229 companies for PB Ratio. This places HOOKIPA Pharma in the top 5% of its industry — outperforming the majority of peers. The industry median PB Ratio is 2.86. HOOKIPA Pharma's value of 0.49 is 82.9% below this benchmark. Historically, HOOKIPA Pharma's own PB Ratio has ranged from 0.27 to 8.05 over the past decade. While the company's 10-year median is 0.92 vs. the industry median of 2.86, HOOKIPA Pharma has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.86, based on 1,229 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. HOOKIPA Pharma's current PB Ratio of 0.49 is 82.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on HOOKIPA Pharma and its competitors. For the Biotechnology industry, the median PB Ratio is 2.86 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. HOOKIPA Pharma's current PB Ratio is 0.49, which is 47% below median its own 10-year median of 0.92. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is HOOKIPA Pharma stock overvalued right now?
Based on GuruFocus' analysis, HOOKIPA Pharma (HOOK) is currently considered Possible Value Trap. The stock's GF Value™ is $2.78, compared to a current price of $1.15 — trading 58.6% below its estimated fair value. The current PB Ratio is 0.49, which is 47% below median its 10-year median of 0.92 and 82.9% below the Biotechnology industry median of 2.86. HOOKIPA Pharma's overall GF Score™ is 50/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For HOOKIPA Pharma (HOOK), the current PB Ratio is 0.49 as of Jun. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is HOOKIPA Pharma (HOOK) Overvalued in 2026?
Based on GuruFocus' analysis, HOOKIPA Pharma stock appears to be undervalued.
The current stock price of $1.15 is trading 58.6% below its estimated GF Value™ of $2.78.
GuruFocus considers HOOKIPA Pharma to be Possible Value Trap.
Key valuation signals for HOOK:
PB Ratio: 0.49 (47% below median its 10-year median of 0.92)
GF Value™: $2.78 vs. price of $1.15 (58.6% below fair value)
Industry Position: 82.9% below the Biotechnology median (#61 of 1229)
No single metric tells the full story. See the HOOK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
HOOKIPA Pharma Inc is a clinical-stage biopharmaceutical company developing a class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform that is designed to reprogram the body's immune system. The company's product candidates are designed to induce specific, robust and durable CD8+ T cells and antibodies to eliminate cancers and serious infectious diseases. Its pipeline includes biological therapies for oncology, targeting human papillomavirus type 16-positive (HPV16+) cancers, KRAS mutated cancers, and other targets. In addition, It is also focused to develop therapies that are intended to provide functional cures for hepatitis B virus (HBV) and human immunodeficiency virus-1 (HIV-1).
50GF Score
Get the complete analysis for HOOK
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HOOK has been successfully added to your 
